Category Archives: IMPROVE-It 2012 Vytorin FDA to require outcomes data fo

And — Speaking of "Long Times" — Improve-It 2012

I forgot to note that overnight, the outcomes study on Vytorin crossed another major milestone — IMPROVE-It is now less-than 1,500 days away from completion.

Well, that ought to ease investors’ minds, eh?

Yep — take a look at the count-down clock in the lower-left margin — 1,499 days, and counting. . . . counting. . . .

Then we’ll know whether Vytorin improves outcomes. It will have been on the market for about eight ten years (measuring from Zetia’s original US FDA approval date — kudos, Commenter No. 1!) by the time we know whether it really works — works to improve patients’ odds of avoiding heart-attacks.

And — Speaking of "Long Times" — Improve-It 2012

I forgot to note that overnight, the outcomes study on Vytorin crossed another major milestone — IMPROVE-It is now less-than 1,500 days away from completion.

Well, that ought to ease investors’ minds, eh?

Yep — take a look at the count-down clock in the lower-left margin — 1,499 days, and counting. . . . counting. . . .

Then we’ll know whether Vytorin improves outcomes. It will have been on the market for about eight ten years (measuring from Zetia’s original US FDA approval date — kudos, Commenter No. 1!) by the time we know whether it really works — works to improve patients’ odds of avoiding heart-attacks.

And — Speaking of "Long Times" — Improve-It 2012

I forgot to note that overnight, the outcomes study on Vytorin crossed another major milestone — IMPROVE-It is now less-than 1,500 days away from completion.

Well, that ought to ease investors’ minds, eh?

Yep — take a look at the count-down clock in the lower-left margin — 1,499 days, and counting. . . . counting. . . .

Then we’ll know whether Vytorin improves outcomes. It will have been on the market for about eight ten years (measuring from Zetia’s original US FDA approval date — kudos, Commenter No. 1!) by the time we know whether it really works — works to improve patients’ odds of avoiding heart-attacks.